*****
TODAY’S NEWS
WebMD makes some changes to rigged depression test. This kind of thing is just stupid. Come on, people.
Astellas looking to buy OSI. Smart pharma companies are looking up to gain a strong oncology franchise.
Shire gets approval for its Gaucher drug.
AstraZeneca buying out Merck‘s interest in certain jointly-marketed products.
RECOMMENDED
Executive Leadership – Yes, even the top echelon folks need coaching and training to continue their development. We’ve got the providers you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Some new primary-care doctors are going for a cash-only practice (from KevinMD). Can hardly blame them – soon all the government/regulatory/insurance nonsense will bring back the barter system!
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Thanks for the daily news summary. I enjoy your crib notes of trending topics in the pharma-sphere.
But, today deserves high praise for bringing attention to “The Carlat Psychiatry Blog” and his callout of recent WebMD/Lilly activities around a recent posted depression test on the WebMD’s site. Too often we don’t challenge each other to snap back into line. And, even less frequently do we gain insight into constructive criticism that holds ground as a solid learning opporutnity.
Seemingly gray, not-well-defined areas of opportunities exist for each of us every day. It’s one thing to push an envelope, it’s something else to not take the “straight-face test”. As you stated with such clarity …. “Come on, people” … indeed.
Keep ’em coming!
Marian
http://twitter.com/MarianCutler